Loading company
HUTCHMED (China) Ltd
HCM · Nasdaq · ·
$14.16+0.2%Sep 29 close
- 1M
- +18.9%
- 6M
- -6.5%
- 1Y
- -11.3%
- 5Y
- -62.0%
HCM · Nasdaq · ·
$14.16+0.2%Sep 29 close
The quarter ending December 31, 2019, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2019 | 3 months toDec 31, 2018 | Change |
|---|---|---|---|
| Total Revenue | $53.3M | $53.1M | +0.44% |
| Profit | -$29.6M | -$16.5M | -78.77% |
| Profit per share | -$0.25 | -$0.10 | -150.00% |
| Free Cash Flow | -$20.3M | -$16.9M | -20.57% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
HUTCHMED (China) Ltd has no earnings call transcript available.
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, and the first of which is also approved around the world including in the US, Europe and Japan.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K HUTCHMED (China) Ltd filed on July 30, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.